Stockscreener 앱 받기
32.14
0.66%
0.21
시장 영업 전:
31.75
-0.39
-1.21%
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Getting Closer To Key Technical Benchmark - Investor's Business Daily
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics (VKTX) Is Up 9.1% After Advancing VK2735 As Rival Obesity Drug Stumbles - simplywall.st
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today - Yahoo Finance
Viking Therapeutics: The High-Stakes Weight Loss Contender - MarketBeat
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus - simplywall.st
Viking Therapeutics Gains Ground Amid Novo Nordisk's Clinical Setback - AD HOC NEWS
Is Viking Therapeutics (VKTX) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - The Motley Fool
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics Advances VK2735 As Phase 3 Trials Shape Valuation - simplywall.st
Viking Therapeutics Gains Momentum as Rival Stumbles - AD HOC NEWS
Viking Therapeutics Shares Surge as Rival Stumbles in Obesity Drug Race - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A 169% Upside Potential Sparks Interest - DirectorsTalk Interviews
Viking Therapeutics, Inc. (VKTX): A bull case theory - MSN
Viking Therapeutics Stock Jumps 11% After Obesity Drug Update: Analysts See $93 Target - TIKR.com
Viking Therapeutics Gains Momentum in Competitive Weight-Loss Drug Arena - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Bitget
The Ultimate Biotech Stock to Buy With $500 Right Now - AOL.com
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. - The Globe and Mail
Viking Therapeutics Targets Expansion Amid Market Challenges - timothysykes.com
Viking Therapeutics Stock Gains Amid Obesity Drug Buzz - Benzinga
Viking Therapeutics (VKTX) Valuation In Focus As VK2735 Advances In GLP 1 Weight Loss Trials - simplywall.st
Why Viking Therapeutics Stock Is Climbing Again - TipRanks
Why Viking Therapeutics Stock Is Up More Than 9% Today - Yahoo Finance
Viking Therapeutics (VKTX) Sees Significant 10.7% Share Price In - GuruFocus
Viking Therapeutics Stock (VKTX) Opinions on Novo Nordisk CagriSema Setback - Quiver Quantitative
Viking Therapeutics Shares Surge as Rival's Obesity Drug Stumbles - AD HOC NEWS
Viking Therapeutics: VK2735 Promise Meets Execution Risk - AlphaStreet News
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds - Nasdaq
Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate - AOL.com
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Viking Therapeutics Surges as Obesity Drug Hopes Rise - TipRanks
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - AOL.com
Viking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity - MSN
Can Viking Therapeutics Really Soar 300%? Why Wall Street Is Betting Big on This Biotech Stock - NAI500
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
Is Viking Therapeutics Stock Really Going to $125? - AOL.com
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
$100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics plans to advance oral obesity drug to late-stage testing - MSN
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast - Investing.com Nigeria
0.11%
6.00%
자본화:
|
볼륨(24시간):